Nicholas Saraceno, Editor

A cohort study investigates whether or not the prevalence of these types of illnesses can vary among individuals who are COVID-positive versus negative.

The pre-approval pertains to a solid oral dose product that the CDMO will manufacture for a global pharmaceutical company.

The acquisition provides Ardian with greater insight into the life science industry.

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

The San Antonio facility will be taking this biomanufacturing initiative by the end of Q3 2024.

The deal exponentially grows the CDMO’s biopharma capabilities.

In a transaction valued at $250 million, the deal makes Grünenthal the new owner of Movantik, which treats OIC in adult patients with chronic non-cancer pain.

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, dives into efficiencies presented by at-home diagnostic tests.

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, discusses findings of a new physician survey that the company conducted.

The agreement revolves around providing and maintaining supply chain transparency.

The financial commitment includes a pair of expansion plans occurring in the United States and Europe.

The 50,000 square-foot facility has the ability to handle various batch sizes and dosage forms.

The clinical supply facility undergoes a $25 million expansion, welcoming 32,000 more square feet of temperature-controlled storage.

A study explores the cost-effectiveness of combining methotrexate with various drugs as a way to combat failed methotrexate monotherapy.

The construction of 100,000 square-foot facility will boost the site's filling capacity to 140 million units per year.

The acquisition in the ophthalmology space features a $1.3 billon cash payment, with the potential for an additional $1.7 billion if various milestones are met.

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth’s founder and CEO, discusses how patients are affected by these supply chain bottlenecks, along with ways to mitigate these complications.

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth's founder and CEO, offers his thoughts surrounding the lack of supply.

The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process.

An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time.

Expansion of these offerings will occur at the company’s 60,000 square-foot Lincolnshire Center of Excellence

Double-digit, year-on-year growth is now on a six-month streak.

An observational, retrospective cohort study undergoes this investigation in individuals 24 years of age or older.

The investment is expected to help enhance the company temperature-controlled services in the Netherlands, France, Italy, and Hungary.

The Stelara biosimilar will be commercialized by Sandoz, and is expected to launch by February 2025 for multiple indications, including for the treatment of adult patients with active psoriatic arthritis.

The deal provides the CDMO with ownership of the Lexington facility, allowing for late-phase and commercial gene therapy development and manufacturing of a branded severe Hemophilia B product.

A cross-sectional study evaluates the difference in clinical outcomes and demographics between pediatric RSV patients during these multiple timeframes.

The CRDMO will contribute cell discovery services that will benefit clinical development of novel technologies.

Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform.

The company’s latest investment—featuring new cGMP suites at its Devens, MA plant—is valued at $30 million.